Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
19 December 2022Website:
http://www.lipella.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | Mon, 01 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
LIPO Latest News
Clinical testing of LP-310 expected to commence in mid-2024 Patient recruitment is underway for Phase 2a multicenter, dose-ranging study PITTSBURGH, PA., May 31, 2024 — Lipella Pharmaceuticals Inc.
Clinical testing of LP-310 expected to commence in mid-2024 Patient recruitment is underway for Phase 2a multicenter, dose-ranging study PITTSBURGH, May 31, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the successful completion of its first Site Initiation Visit (SIV) for the Phase 2a trial evaluating LP-310 in the treatment of Oral Lichen Planus (OLP). With clearance received from the central Institutional Review Board (IRB), the Phase 2a trial is set to commence with site qualifications completed and patient recruitment underway.
Abstract highlighting new preclinical data from LP-50 in non-muscle invasive bladder cancer PITTSBURGH, Pa., May 29, 2024 – Lipella Pharmaceuticals Inc.
PITTSBURGH, May 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces an abstract publication at the 2024 American Society of Clinical Oncology (ASCO) annual meeting, taking place from May 31 - June 4 in Chicago, IL, and online. Lipella's abstract, titled “Intravesical Administration of Pembrolizumab for Bladder Tumor- A Potential Strategy to Minimize Drug Toxicity” highlights new preclinical results from LP-50 (intravesical pembrolizumab) in induced murine non-muscle invasive bladder cancer (NMIBC).
PITTSBURGH, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc., (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a pioneering, clinical-stage pharmaceutical company, announced today that Chief Medical Officer Dr. Michael Chancellor will present at the PropThink Digital Investor Conference's key opinion leader (KOL) discussion on Friday, February 23, 2024, at 2 PM ET. Dr. Chancellor's presentation will be titled: “Urologist Talks Bladder Cancer and Lasting Side Effects”.
Shares of Lipella Pharmaceuticals Inc. LIPO, +51.55% rocketed 52.2% higher in very active tracing Friday, after the Pittsburgh-based biotechnology company's investigational new drug application for its oral lichen planus treatment was approved by the U.S. Food and Drug Administration. Trading volume in the stock, which was the best performer on the major U.S. exchanges, blasted higher to 30.7 million shares, compared with the full-day average of about 6,400 shares.
What type of business is Lipella Pharmaceuticals Common Stock?
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
What sector is Lipella Pharmaceuticals Common Stock in?
Lipella Pharmaceuticals Common Stock is in the Healthcare sector
What industry is Lipella Pharmaceuticals Common Stock in?
Lipella Pharmaceuticals Common Stock is in the Biotechnology industry
What country is Lipella Pharmaceuticals Common Stock from?
Lipella Pharmaceuticals Common Stock is headquartered in United States
When did Lipella Pharmaceuticals Common Stock go public?
Lipella Pharmaceuticals Common Stock initial public offering (IPO) was on 19 December 2022
What is Lipella Pharmaceuticals Common Stock website?
https://www.lipella.com
Is Lipella Pharmaceuticals Common Stock in the S&P 500?
No, Lipella Pharmaceuticals Common Stock is not included in the S&P 500 index
Is Lipella Pharmaceuticals Common Stock in the NASDAQ 100?
No, Lipella Pharmaceuticals Common Stock is not included in the NASDAQ 100 index
Is Lipella Pharmaceuticals Common Stock in the Dow Jones?
No, Lipella Pharmaceuticals Common Stock is not included in the Dow Jones index
When does Lipella Pharmaceuticals Common Stock report earnings?
Next earnings report date is not announced yet